17 results about "Undifferentiated cell" patented technology

The invention provides a preparation method of a cell for expressing a chimeric antigen receptor. The preparation method comprises the following steps: (1) enabling the cell to be in contact with an activating agent for activation; (2) contacting the cell with a nucleic acid molecule for coding the CAR, the nucleic acid molecule for coding the CAR being on a non-viral vector, and obtaining the cell containing the nucleic acid molecule; and (3) harvesting cells. Wherein the step (3) is not later than 72 hours after the step (1) is started. Compared with cells prepared by other similar methods, the cells in the step (3) show a higher CAR positive rate, a higher proportion of undifferentiated cell phenotypes, a lower proportion of depleted cells and a stronger amplification ability.

The present invention relates to a method for preparing organ-specific mesenchymal cells from pluripotent stem cell-derived intestinal organoid stromal cells. By using cells derived from stromal cell layers adjacent to intestinal organoids for differentiation into organ-specific mesenchymal cells, the present invention can greatly increase the efficiency of differentiation into stromal cells through the regulation of retinoic acid (RA) and hedgehog (HH) signaling pathways, and can increase the expression of organ-specific markers without exhibiting undifferentiated state cell characteristics, and thus mesenchymal cells having well-simulated biological characteristics can be prepared.

A cell image analysis method includes converting a first image into a label image by performing a segmentation process to identify a region of a cell that has already started differentiation and a region of an undifferentiated cell in the first image, acquiring a shape feature amount from the label image, and determining whether or not a cell colony includes a colony region that is a candidate for a search target based on the shape feature amount and a determination criterion.

Provided are marker genes capable of detecting the survival / mixing of undifferentiated cells in a population of differentiated cells. By using at least one gene selected from LINC00678 and PRDM14 as an undifferentiated marker, undifferentiated cells present in a population of differentiated cells are detected. Also provided are a method for detecting undifferentiated cells, a method of use as an undifferentiated marker, an undifferentiated cell detection kit, and a method for sorting an undifferentiated cell line.

The invention relates to the technical field of biology, and particularly discloses a method for preparing mesenchymal stem cells by utilizing differential settlement sorting cell balls. According to the method, the differential sedimentation method is adopted, the diameters of the embryoid cell balls are sorted according to the size, the diameter uniformity of the embryoid cell balls is remarkably improved, and then the uniformity and stability of subsequent differentiation products are improved. According to the method provided by the invention, reagent components are clear, facility requirements are simple, differentiation efficiency is high, the iMSC conforming to the identification standard can be obtained by rapidly differentiating for 20 days, the obtained iMSC is good in uniformity and less in undifferentiated cell residue, and the method has potential value in clinical transformation application.

The invention relates to a method for obtaining a dental prosthesis comprising a crown and a root. The method comprises at least one step of guiding undifferentiated cells or keratinocytes and at least one step of three-dimensional printing, preferably 3D bioprinting of the dental prosthesis. Furthermore, the invention relates to a dental prosthesis obtained using said method, as well as to bio-inks suitable for three-dimensional printing (3D), preferably for 3D bioprinting.

The invention provides a C2BBe1 intestinal cell reprogramming method and system, and aims to solve the technical problems of low reprogramming efficiency, unstable reprogramming result, difficulty in truly simulating in-vivo real conditions and difficulty in driving intestinal epithelial cell physiological morphology and differentiation maintenance in current intestinal tissue modeling. An in-vivo intestinal canal model and an in-vitro gas-liquid exchange interface model are constructed, real in-vivo conditions can be simulated, a crypt-villus topological structure can be reconstructed spontaneously, and spatial heterogeneity and cell lineage distribution of intestinal epithelium can be simulated truly. After specific mechanical stimulation characteristic verification of the intestinal canal at different development stages is carried out, a verification result is obtained, and actual in-vitro inoculation is carried out on the basis of the verification result. And finally undifferentiated cells can be directly reprogrammed, so that the dependence on pluripotent stem cells and a complex induction process in a traditional method is avoided, and the reprogramming efficiency and stability are remarkably improved.

The invention relates to a method for in vitro characterization of a eukaryotic biological micro-tissue by imaging using a phase measurement technique without a reference beam, and the use of this method in particular for: - controlling the quality of a micro-tissue, - measuring the increase in the biomass of a micro-tissue during its culture and / or its amplification, - monitoring the differentiation and / or the organization of a micro-tissue during its maturation, - determining the phenotype of cells in the micro-tissue, and / or - confirming the absence of undifferentiated cells in the micro-tissue.

Provided is a technique for producing an organoid that is larger in size and more functionally excellent than conventional organoids. The present invention employs a method for producing an organoid, the method comprising: a step (A1) for culturing an organoid, in which an organoid produced from undifferentiated cells, mesenchymal cells, and vascular cells that differentiate into a first organ is brought into a secretion factor secreted from a second organ; and a step (A2) for culturing the organoid cultured in the step (A1). In the step (A1) and the step (A2), the dissolved oxygen partial pressure of a medium in contact with the organoid is 20% or less. The dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A1) is lower than the dissolved oxygen partial pressure of the medium in contact with the organoid in the step (A2).

The invention relates to a process for the preparation of an extract obtained from undifferentiated cell suspension cultures of clary sage, to the extract obtained by this process, to the use of this extract as an active ingredient in the prevention and / or treatment of inflammation or microbial infections, to a pharmaceutical composition comprising said extract, to a sanitizing composition comprising said extract, to the use of said sanitizing composition for sanitizing a surface or increasing the surface's resistance to microbe transmission, to the cosmetic use of said extract as an anti-aging active ingredient and to a cosmetic composition comprising said extract

The present invention relates to methods and devices for size-based isolation of undifferentiated cells from a population of cells using curvilinear microfluidic channels. The curvilinear microfluidic channel may be a spiral microfluidic channel. The differentiated cells are spinal progenitor cells (SCPCs), neural progenitor cells (NPCs), and / or cells differentiated therefrom. The method may include flowing an input cell population through first and second curvilinear microfluidic channels connected in sequence and in fluid communication, where the first channel is coupled to an inlet and the second channel is coupled to one or more outlets, where the first curvilinear microfluidic channel has a cross-sectional area smaller than a cross-sectional area of the second curvilinear microfluidic channel.

The present application relates to the field of biological medicine, and particularly relates to a composition for reducing stem cell transplantation rejection and application. The composition can reduce the proliferation and activation ability of T cells in combination with peptide I, peptide II and compound extract group. By combining with specific receptors on the surface of T cells, the calcium modulator phosphatase / NFAT pathway is blocked, the secretion of IFN-gamma and IL-2 and other cytokines is reduced, so that the proliferation and activation of T cells are inhibited. At the same time, the composition can induce the production of regulatory T cells and suppressor T cells, up-regulate the expression of TGF-beta and IDO, promote the differentiation of undifferentiated T cells into Treg cells, and enhance the inhibitory function of Treg cells; can also regulate Th1 / Th2 cytokine secretion, reduce Th1 type cytokine secretion, increase Th2 type cytokine secretion, and induce immune tolerance of the body.

The invention relates to methods and devices for size-based separation of undifferentiated cells from a population of cells using curvilinear microfluidic channels. The curvilinear microfluidic channels may be a spiral microfluidic channels. The differentiated cells are spinal cord progenitor cells (SCPCs), neural progenitor cells (NPCs) and / or cells differentiated therefrom. The method may comprise flowing an input population of cells through first and second sequentially connected and fluidically communicating curvilinear microfluidic channels, wherein the first channel is coupled to an inlet and the second channel is coupled to one or more outlets, wherein the first curvilinear microfluidic channel has a smaller cross-sectional area than the second curvilinear microfluidic channel.

Provided is a method for detecting or removing undifferentiated cells remaining in a neural cell population induced from pluripotent stem cells, the method comprising: (1) a step for bringing a sugar chain-binding molecule into contact with the neural cell population; and (2) a step for detecting or removing cells having the sugar chain-binding molecule bound thereto. In the method, (a) the sugar chain-binding molecule binds to Lewis X, and the undifferentiated cells are undifferentiated neural progenitor cells, or (b) the sugar chain-binding molecule binds to N-acetyllactosamine or poly-N-acetyllactosamine, and the undifferentiated cells are mesenchymal-like cells.

Provided is a method for preparing cells expressing a chimeric antigen receptor (CAR), comprising: (1) making cells in contact with an activator for activation; (2) making the cells in contact with nucleic acid molecules encoding a CAR, wherein the nucleic acid molecules encoding the CAR are on non-viral vectors, to obtain cells comprising the nucleic acid molecules; and (3) harvesting the cells. Step (3) is carried out no later than 72 hours upon the start of step (1). Compared with cells prepared by other similar methods, the cells of step (3) show a higher CAR positive rate, a higher proportion of undifferentiated cell phenotypes, a lower proportion of exhausted cells and a greater expansion capability.

The application of PINK1 / OPTN / NDP52 pathway to improve mitochondrial autophagy in Alzheimer's disease involves the field of disease treatment for Alzheimer's disease. First, in animal experiments, APP / PS1 transgenic mice were used to intervene with the traditional Chinese medicine Zhinaoshen to detect changes in the learning and memory abilities of mice and observe changes in the morphology of hippocampal neurons. 25‑35 After treatment, undifferentiated PC12 cells were observed for changes in cell morphology. Both experiments detected oxidative damage to neurons, mitochondrial autophagy, and mitochondrial function-related proteins to clarify the effects of drugs on the inhibition of mitochondrial autophagy disorders in AD model mice, thereby exploring and broadening the therapeutic drugs for Alzheimer's disease. Therefore, drugs that upregulate the PINK1 / OPTN / NDP52 pathway to improve mitochondrial autophagy in cells can be used in the preparation of therapeutic drugs for Alzheimer's disease.

The invention relates to the field of biological medicine, in particular to a composition for reducing stem cell transplantation rejection and application. The composition is combined with the peptide I, the peptide II and the compound extract group, so that the proliferation and activation capacities of T cells can be reduced. By combining with a specific receptor on the surface of a T cell, a calmodulin / NFAT pathway is blocked, and secretion of cell factors such as IFN-gamma and IL-2 is reduced, so that proliferation and activation of the T cell are inhibited. Meanwhile, the composition can induce generation of regulatory T cells and inhibitory T cells, promote differentiation of undifferentiated T cells to Treg cells by up-regulating expression of TGF-beta and IDO, and enhance the inhibition function of the Treg cells; th1 / Th2 cytokine secretion can also be regulated, so that Th1 type cytokine secretion is reduced, Th2 type cytokine secretion is increased, and body immune tolerance is induced.